Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07194044 · ClinicalTrials.gov registry record · Phase 1
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
A Phase 1 study of Metastatic Ewing Sarcoma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 17
- Study locations
NCT07194044 is a Phase 1 study of Metastatic Ewing Sarcoma that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 15 participants, below the 256-participant average among 3 other Metastatic Ewing Sarcoma trials with a reported enrollment target (94% lower). The trial reports 17 study locations across 11 states.
The verdict
NCT07194044, a Phase 1 study of Metastatic Ewing Sarcoma, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 17
- Study locations
Study Summary
This single arm study is designed to demonstrate the feasibility of a radically different approach for an exceptionally high-risk subset of MES with widely metastatic disease (WMES). We incorporate the use of evolutionary principles that apply to species and population dynamics as related to adaptation and extinction to populations of cancer cells that similarly adapt and that we are attempting to make extinct, resulting in a cure for the patient. Such principles include an initial intense first strike to deplete the bulk of the cancer cells, followed by a series of sequential second strikes towards eliminating residual, resistant populations, followed by a prolonged period of maintenance chemotherapy to eliminate any remnant cells, using agents generally regarded to be active against newly diagnosed ES.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Doxorubicin
- DRUG Vincristine
- DRUG Ifosfamide
- DRUG Actinomycin
Study Locations (17)
Florida
- University of Florida - Gainesville
- Nemours Jacksonville - Jacksonville
- University of Miami - Miami
- Moffitt Cancer Center - Tampa
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
- Montefiore Medical Center - The Bronx
North Carolina
- University of North Carolina - Chapel Hill
- Levine Cancer Institute - Charlotte
Ohio
- Cleveland Clinic Children's - Cleveland
- Nationwide Children's Hospital - Columbus
Alabama
- University of Alabama at Birmingham (Children's of Alabama) - Birmingham
Arizona
- Phoenix Children's Hospital - Phoenix
Connecticut
- Connecticut Children's Medical Center - Hartford
Kentucky
- University of Kentucky - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-02 |
| Est. Completion | 2030-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07194044
The ClinicalTrials.gov registry entry for NCT07194044 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 256-participant average among 3 other Metastatic Ewing Sarcoma trials with a reported enrollment target (94% lower). The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Ewing Sarcoma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT07194044 reports 17 study locations spanning 11 distinct geographic areas - top geographies include Florida, New York, North Carolina.
Frequently Asked Questions
What is clinical trial NCT07194044 about?
NCT07194044 is a clinical study titled "Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes". This single arm study is designed to demonstrate the feasibility of a radically different approach for an exceptionally high-risk subset of MES with widely metastatic disease (WMES). We incorporate the use of evolutionary principles that apply to species and population dynamics as related to adaptat...
What is the current status of trial NCT07194044?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2026-02. Estimated completion is 2030-10.
What conditions does trial NCT07194044 study?
This clinical trial studies the following conditions: Metastatic Ewing Sarcoma.
What interventions are being tested in trial NCT07194044?
The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin (DRUG), Vincristine (DRUG), Ifosfamide (DRUG), Actinomycin (DRUG).
Who is sponsoring clinical trial NCT07194044?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07194044 being conducted?
This trial has 17 study locations across Alabama, Arizona, Connecticut, Florida, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Ewing Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
ACTIVE NOT RECRUITING · Phase 3
-
Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body
ACTIVE NOT RECRUITING · Phase 2
-
Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.